文献速递肾小球疾病

肾脏疾病管理中的免疫抑制原则:2022年核心课程

Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022.
PubMed 文献 · Am J Kidney Dis · 2022-04-16

本文为2022年核心课程,阐述肾小球疾病免疫抑制治疗需高度个体化。内容涵盖烷化剂、抗代谢药、钙调神经磷酸酶抑制剂、抗CD20治疗、补体抑制剂、糖皮质激素及静脉免疫球蛋白的作用机制、药代动力学、监测要点与不良反应,并讨论诱导与维持方案及根据疾病轨迹调整治疗。总体原则为在减轻疾病与避免伤害间取得平衡,孕妇、老年及透析患者需特别权衡并加强监测。

要点

  • 肾小球疾病免疫抑制治疗需高度个体化,及时识别与管理对减轻肾损伤至关重要。
  • 肾内科医生需熟悉烷化剂、抗代谢药、钙调神经磷酸酶抑制剂、抗CD20治疗、补体抑制剂、糖皮质激素及静脉免疫球蛋白的作用机制、药代与监测。
  • 孕妇、老年及透析患者对免疫抑制尤其敏感,需高度权衡治疗策略并加强不良反应监测。

核心结论

  • 免疫抑制策略的总体原则是在减轻疾病与避免意外伤害之间取得平衡。

研究设计与样本

  • 本文为2022年核心课程,综述肾小球疾病免疫抑制管理的原则。

主要发现

  • 肾小球疾病免疫抑制管理需高度个体化,及时识别与管理对减轻肾损伤至关重要。
  • 需熟悉烷化剂、抗代谢药、钙调神经磷酸酶抑制剂、抗CD20治疗、补体抑制剂、糖皮质激素及静脉免疫球蛋白的作用机制、药代动力学与药效学、监测要点及不良反应。
  • 需理解肾小球疾病中诱导与维持方案的治疗决策,并根据疾病轨迹与后续反应进行调整。
  • 孕妇、老年患者及透析患者对免疫抑制尤其敏感,需高度权衡治疗策略并加强不良反应监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of immunosuppression utilized in glomerular diseases requires highly nuanced care. Timely recognition and management of these disorders is essential to mitigate the extent of kidney damage. This involves being cognizant of the various classes of immunosuppression, which includes alkylating agents, antimetabolites, calcineurin inhibitors, anti-CD20 therapy, complement inhibitors, corticosteroids, and intravenous immunoglobulin. The mechanisms of action of these drugs, along with associated pharmacokinetics and pharmacodynamics, facets of monitoring, and adverse effects are important aspects with which nephrologists are required to be well versed. In addition, an understanding of therapeutic decisions such as induction and maintenance regimens in the setting of glomerular disease and alteration based on trajectory of disease and subsequent response is imperative. The overarching principle of these strategies of immunosuppression is to achieve a balance of disease mitigation without exposure to inadvertent harm. Special groups such as pregnant women, elderly patients, and patients treated with dialysis are especially susceptible to immunosuppression and thus need highly weighed therapeutic strategies and enhanced surveillance of adverse effects.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kant S, Kronbichler A, Geetha D, et al. Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. Am J Kidney Dis. 2022. PMID: 35440396. doi:10.1053/j.ajkd.2021.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。